GleamWall
中文EN

RDGL VIVOS INC

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1449349 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY392.2%
TTM net income YoY-27.1%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR69.3%
Net income 3-yr CAGR—

Margins

Gross margin6.8%
Operating margin-2,414.0%
Net margin-3,032.9%
FCF margin—
EBITDA margin—

Returns

ROE-180.2%
ROA-167.1%
ROIC (approx.)-2,040.3%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets9.7%
Debt / equity0.00x
Current ratio12.33x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.60x
Accruals ratio-66.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$68,379$27,995
Cost of revenue$128,134$30,979
Gross profit-$59,755-$2,984
R&D expense$352,232$324,629
SG&A expense$296,556$241,824
Operating income-$3.17M-$2.60M
Pretax income-$3.07M-$2.91M
Net income-$3.07M-$2.91M
EBITDA-$3.16M—
EPS (basic)-0.01-0.01
EPS (diluted)-0.01-0.01
Weighted avg. shares (diluted)452.72M409.67M
Banking
Net interest income$99,030$74,936
Balance sheet
Cash & equivalents$1.56M$2.21M
Receivables$22,331$10,326
Inventory$57,257—
Current assets$1.65M$2.23M
PP&E, net$102,811—
Total assets$1.87M$2.23M
Current liabilities$117,892$86,209
Total liabilities$206,743$86,209
Shareholders' equity$1.66M$2.15M
Shares outstanding455.49M440.87M
Cash flow statement
Operating cash flow-$2.06M-$1.68M
Capital expenditure$103,185—
Free cash flow-$2.16M—
Investing cash flow-$103,185—
Financing cash flow$1.51M$2.30M
Depreciation & amortization$374—

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.